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Evidence from multiple laboratories has accumulated to show that mosaic neuronal 
aneuploidy and consequent apoptosis characterizes and may underlie neuronal loss in 
many neurodegenerative diseases, particularly Alzheimer’s disease and frontotemporal 
dementia. Furthermore, several neurodevelopmental disorders, including Seckel 
syndrome, ataxia telangiectasia, Nijmegen breakage syndrome, Niemann–Pick type C, 
and Down syndrome, have been shown to also exhibit mosaic aneuploidy in neurons 
in the brain and in other cells throughout the body. Together, these results indicate that 
both neurodegenerative and neurodevelopmental disorders with apparently different 
pathogenic causes share a cell cycle defect that leads to mosaic aneuploidy in many cell 
types. When such mosaic aneuploidy arises in neurons in the brain, it promotes apoptosis 
and may at least partly underlie the cognitive deficits that characterize the neurological 
symptoms of these disorders. These findings have implications for both diagnosis and 
treatment/prevention.
Keywords: Alzheimer’s disease, Mosaic aneuploidy, Frontotemporal lobar degeneration, Neuronal apoptosis, 
Huntington’s disease (HD)
INTRODUCTION
Age-associated neurodegenerative diseases exhibit different brain pathologies and different 
clinical features, and all are associated with reduced neuronal numbers in specific brain regions. 
Furthermore, when caused by a mutation, each disorder evidently involves a unique pathogenic 
pathway because the mutant proteins are usually involved in very different physiological 
processes. Indeed, the normal function of the associated mutant gene should provide insights 
into that specific disease’s pathogenic pathway. For example, the mutations that cause autosomal 
dominant familial Alzheimer’s disease (FAD) arise in only three genes: the amyloid precursor 
protein (APP) gene, the presenilin 1 (PSEN1) gene, and the presenilin 2 (PSEN2) gene, all 
three of which encode proteins involved in the production of the Aβ peptide, which is the 
main pathogenic molecule of AD (Goate and Hardy, 2012; Hardy, 2017). Specifically, PSEN1 
and PSEN2 are components of the γ-secretase complex, which, together with the β-secretase 
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enzyme, cleaves APP to release Aβ. In contrast, patients 
with frontotemporal dementia (also called frontotemporal 
lobar degeneration, FTLD) exhibit clinical and pathological 
characteristics that differ from AD, and most of the autosomal 
dominantly inherited familial forms of FTLD are caused by 
a mutation in the MAPT/Tau gene, by a mutation in the 
progranulin (PRGN) gene, or by a triplet repeat expansion in 
the C9ORF72 gene, all three of which carry out vastly different 
normal functions in the cell and are also unrelated to the genes 
mutated in FAD (Rademakers et al., 2012). Interestingly, in 
some families, instead of or in addition to FTLD, the triplet 
repeat expansion in the C9ORF72 gene can cause familial 
amyotrophic lateral sclerosis, a motor neuron degenerative 
disease that is associated with cognitive decline only during 
later stages of the disease. Huntington’s disease similarly 
exhibits a unique pathology and clinical course and is caused 
by a triplet repeat expansion in the huntingtin (HTT) gene, 
whose normal function is also apparently different from any 
of the genes associated with familial forms of AD or FTLD 
(Podvin et al., 2019). Thus, there appears to be no common 
feature of neurodegenerative disorders beyond the fact that 
they all result in neuronal loss.
Neurodevelopmental disorders are associated with different 
pathologies and clinical phenotypes, although they again 
usually include microcephaly or another indication of a defect 
in neurogenesis or neuronal survival. For example, ataxia 
telangiectasia and the related disorder Seckel syndrome are 
caused by mutations in the ATM and ATR genes, respectively, 
which encode two related protein kinases. Because both ataxia 
telangiectasia and Seckel syndrome appear to involve the 
loss of neurons, they might be considered neurodegenerative 
disorders without an essential aging component associated 
with their underlying mechanisms. Down syndrome also 
results in reduced neuronal numbers in key brain regions 
during development, and, interestingly, every person with 
Down syndrome develops AD brain neuropathology by age 
30–40, which usually leads to dementia by age 50–60 (Hartley 
et al., 2015; Hithersay et al., 2019).
Because these multiple disorders have different pathologies 
and different clinical symptoms and they involve different 
pathogenic pathways, as evidenced by the different genes 
in which causal mutations can arise, it is reasonable to 
hypothesize that each disorder is distinct and would require 
different approaches to therapy and prevention. However, 
if it were possible to identify a key step that is shared among 
the pathogenic pathways of many neurodegenerative and/or 
neurodevelopmental disorders, then it would also be reasonable 
to hypothesize that insights into the causal mechanism might 
be gained and the potential for a common approach to the 
development of new therapies might be recognized. Of course, 
any shared mechanistic features that are identified must also be 
considered as potentially a mere correlate of the degenerative 
process rather than as an essential step in the pathogenic 
pathways. To distinguish between these two hypotheses, the 
strength of the genetics can be exploited because it is self-
evident that a direct effect of a mutant gene is likely to be part 
of the causal mechanism. If multiple neurodevelopmental 
and neurodegenerative disease-causing mutations impact a 
common pathogenic step, then that step should be considered a 
potential key to preventing the neurodegeneration and should 
thus serve as a prime target for the development of therapeutic 
interventions that could be applied to multiple disorders.
Over the past decade, we and others have identified a 
potential common step in the pathogenic pathways that lead to 
multiple distinct neurodegenerative and neurodevelopmental 
disorders. Specifically, mutations in genes linked to many 
of these disorders have been shown to lead to chromosome 
segregation defects and mosaic aneuploidy in cell types 
throughout the body, including in brain neurons, which likely 
contributes to the neuronal cell loss/apoptosis that underlies 
their neurological features.
Mosaic Aneuploidy in Alzheimer’s Disease
Mosaic aneuploidy/hyperploidy, including trisomy 21, was 
first hypothesized (Potter, 1991) and has been most thoroughly 
investigated in AD (Geller and Potter, 1999; Yang et al., 
2001; Kingsbury et al., 2006; Mosch et al., 2007; Thomas and 
Fenech, 2008; Iourov et al., 2009b; Arendt et al., 2010; Iourov 
et al., 2011). Arendt and colleagues’ extensive study of brains 
from AD patients showed that 20–30% of brain neurons are 
aneuploid during the early preclinical stages of AD and that 
their specific loss in later stages of the disease can account for 
90% of the neuronal atrophy observed at autopsy (Arendt et al., 
2010). Somatic mosaic aneuploidy can also be detected in cells 
from peripheral tissues of AD patients, including fibroblasts, 
peripheral blood mononuclear cells, and buccal cells (Potter 
et  al., 1995; Migliore et al., 1997; Geller and Potter, 1999; 
Migliore et al., 1999; Trippi et al., 2001; Thomas and Fenech, 
2008), providing an opportunity for early detection.
The specific finding that trisomy 21 mosaicism occurs in many 
tissues in AD patients, including in the brain, is highly relevant 
because people with Down syndrome are usually fully trisomic 
for chromosome 21 due to chromosome mis-segregation during 
meiosis, every person with Down syndrome develops AD brain 
neuropathology by 35 years of age, the majority of people with 
Down syndrome develop AD dementia by age 60, and nearly all 
people with Down syndrome who die after age 35 have dementia 
(Glenner and Wong, 1984; Wisniewski et al., 1985; Epstein, 
1990; Hartley et al., 2015; Hithersay et al., 2019). The APP gene 
is located on chromosome 21, and its presence in three copies 
in Down syndrome is presumed to underlie the development of 
early-onset AD in this population (Hartley et al., 2015). Support 
for this conclusion comes from the observation that individuals 
who carry an FAD mutation in the APP gene or who have 
three copies of the APP gene due to a local duplication on one 
chromosome (Rovelet-Lecrux et al., 2006; Sleegers et al., 2006) 
will develop autosomal-dominant early-onset AD. Furthermore, 
individuals who only have 1–10% trisomy 21 cells and show no 
features of Down syndrome also develop early-onset, sporadic 
AD dementia, suggesting that even low levels of trisomy 21 
mosaicism can lead to AD (reviewed in Potter, 1991). Evidence 
that three copies of the APP gene are not only sufficient but also 
necessary to cause AD is provided by the fact that rare individuals 
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who have full trisomy 21 and all of the clinical and physiological 
features of Down syndrome but have only two copies of the APP 
gene due to a localized deletion on chromosome 21 fail to develop 
AD symptoms or AD pathology even at an old age (Prasher et al., 
1998; Doran et al., 2017).
Evidence that an underlying susceptibility to chromosome 
segregation defects may be associated with an increased risk 
of AD was first provided by a study showing that women who 
were 35 or younger when they gave birth to a child with Down 
syndrome have a fivefold increased risk of developing AD later 
in life compared to control mothers or compared to mothers 
who gave birth to a child with Down syndrome after age 35 
(Schupf et al., 1994). More direct support for the idea that 
both trisomy 21 and AD are associated with an underlying 
predisposition for chromosome mis-segregation comes from a 
study of cultured peripheral blood lymphocytes from mothers 
under the age of 35 who gave birth to a child with Down 
syndrome (Migliore et al., 2006). In that study, they used 
fluorescence in situ hybridization probes for chromosomes 21 
and 13 and observed significantly higher levels of chromosome 
non-disjunction involving both chromosomes within the first 
cell cycle in the lymphocytes from mothers who gave birth to 
a child with Down syndrome compared to control mothers 
who had not had a miscarriage and whose children did not 
have genetic disorders (Migliore et al., 2006). Taken together, 
these findings suggest that an underlying predisposition for 
chromosome instability may lead to increased AD risk.
The association of chromosome instability and aneuploidy 
with AD has been reinforced by mechanistic studies. The 
key proteins whose mutant genes cause the majority of 
FAD—the presenilin proteins (PSEN1 and PSEN2) and the 
amyloid precursor protein (APP)—localize to centromeres/
kinetochores, centrosomes, and/or the nuclear envelope 
(Li et al., 1997; Annaert et al., 1999; Honda et  al., 2000; 
Jeong et al., 2000; Kimura et al., 2001; Nizzari et al., 2007a; 
Nizzari et al., 2007b; Young-Pearse et al., 2010; Judge et al., 
2011). Furthermore, FAD mutations in PSEN1 or APP cause 
mitotic spindle abnormalities and aneuploidy in transgenic 
mice and in transfected cells (Boeras et al., 2008; Granic 
et  al., 2010). Treatment of karyotypically normal cells with 
oligomeric Aβ peptide, which is the product of PSEN1- and 
PSEN2-dependent cleavage of APP, also disrupts the mitotic 
spindle and induces chromosome mis-segregation and 
aneuploidy by competitively inhibiting certain microtubule 
motors, particularly Kinesin-5/KIF11/Eg5, MCAK/KIF2C, 
and KIF4A, in both cell culture experiments and in Xenopus 
egg extracts (Boeras et al., 2008; Borysov et al., 2011). These 
mechanistic studies established that cell cycle defects and the 
resultant mosaic aneuploidy are a direct effect of FAD mutant 
genes and are thus likely to be part of the AD pathogenic 
pathway and not merely a correlate of neurodegeneration in 
the brain.
The role of chromosome aneuploidy in AD suggests that 
studying mechanisms that regulate mitosis may lead to novel 
insights into AD. For example, Shugoshin-1 (SGO1) encodes 
a protein that is involved in chromosome cohesion and is 
needed for normal chromosome segregation, and SGO1 
haploinsufficiency leads to chromosome missegregation 
and tumorigenesis (Yamada et al., 2012). Building on the 
role of aneuploidy in AD, Rao and Yamada and colleagues 
hypothesized that SGO1 heterozygous knockout mice may serve 
as a potential model of sporadic late-onset AD, and they indeed 
discovered some AD-related pathology as the mice aged, which 
was associated with prolonged mitosis and spindle checkpoint 
activation (Rao et al., 2018a; Rao et al., 2018b).
Mosaic Aneuploidy in Frontotemporal 
Lobar Degeneration
In addition to AD, mosaic aneuploidy has been observed 
in FTLD (Rossi et al., 2013; Rossi et al., 2014; Caneus et al., 
2018). In earlier studies, mosaic aneuploidy was reported in 
skin fibroblasts and peripheral blood lymphocytes from FTLD 
patients and in splenic lymphocytes from mouse models of 
FTLD-MAPT (Rossi et al., 2008; Rossi et al., 2013; Rossi et al., 
2014). In the subsequent study, we found mosaic aneuploidy and 
associated apoptosis in both neuronal and non-neuronal brain 
cells from patients with familial FTLD who carry a mutation in 
the MAPT/Tau gene (Caneus et al., 2018). Expression of FTLD-
causing mutant MAPT induced mitotic spindle abnormalities, 
chromosome mis-segregation, aneuploidy, and apoptosis in 
neurons and other cells in the brains of transgenic mice and in 
transfected cells (Caneus et al., 2018). Furthermore, we showed 
in our FTLD study that apoptosis occurs in the same brain 
neurons that are aneuploid and that, in cultured cells expressing 
FTLD-causing mutant forms of human MAPT, apoptosis follows 
and depends upon aneuploidy-generating cell cycle defects 
(Caneus et al., 2018). If the cell cycle is blocked by inhibiting 
the interaction between MDM2 and p53 by treatment with 
low doses of Nutlin-3 at 24 h after expression of FTLD-causing 
mutant MAPT, no aneuploid cells arise (Caneus et al., 2018). 
Importantly, treatment with Nutlin-3 also blocks apoptosis, 
indicating that the toxicity of mutant MAPT depends on cells 
aberrantly proceeding through the cell cycle and becoming 
aneuploid.
Evidence linking neuronal aneuploidy, neurodegeneration, 
and MAPT was reported recently by two other groups in 
Drosophila models of FTLD. Specifically, a study by Bougé 
and Parmentier showed that excess Tau causes mitotic spindle 
defects, aneuploidy, and apoptosis in neurons by inhibiting 
the microtubule-dependent motor protein Kinesin-5 (Bouge 
and Parmentier, 2016). Similar results have been reported 
by Malmanche et al. who examined photoreceptors and 
brain neurons in Drosophila and found that adult-onset 
neurodegeneration mediated by MAPT overexpression 
included the generation of aneuploid cells (Malmanche 
et  al., 2017). The former result is of particular interest in 
view of our previous finding that Aβ induces chromosome 
mis-segregation and aneuploidy by competitively inhibiting 
the activity of Kinesin-5/KIF11/Eg5 (Borysov et al., 2011). 
Thus, causal mutations leading to AD and FTLD-MAPT 
appear to lead to chromosome mis-segregation, aneuploidy, 
and apoptosis through inhibition of the same target enzyme: 
Kinesin-5/KIF11/Eg5.
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In addition to MAPT-FTLD, we have found that mosaic 
neuronal aneuploidy and dependent apoptosis are also 
characteristic of brains of individuals with sporadic FTLD or 
with FTLD caused by mutations in PRGN or by triplet repeat 
expansions in C9ORF72 (Elos and Caneus et al., unpublished 
results, manuscript in preparation).
It is likely that other neurodegenerative diseases are also 
associated with mosaic aneuploidy in the brain. For example, 
autism spectrum disorder (Yurov et al., 2007; Iourov et al., 
2008), ataxia telangiectasia (McConnell et al., 2004; Iourov 
et al., 2009a; Iourov et al., 2009b), and Lewy body disease, 
which includes Parkinson’s disease (Yang et al., 2015), have 
all been reported to exhibit either general hyperploidy or 
mosaic aneuploidy for numerous chromosomes in brain and/
or peripheral tissues. Our laboratory also has preliminary 
evidence for mosaic aneuploidy in both brain cells and 
fibroblasts from Huntington’s disease patients (Elos and 
Caneus et al., unpublished results, manuscript in preparation).
Mosaic Aneuploidy in Neurodevelopmental 
Disorders
Mosaic aneuploidy in neurons and other types of cells also 
characterizes neurodevelopmental disorders. For example, loss-
of-function mutations in the ataxia telangiectasia mutated and 
Rad3-related (ATR) encoded kinase cause Seckel syndrome, 
a rare autosomal recessive disorder characterized by pre- 
and postnatal growth delays, microcephaly, and intellectual 
disability. Loss of ATR function and of the related kinase ataxia 
telangiectasia mutated (ATM) have been linked to defective 
DNA repair, which has been assumed to cause the genomic 
instability, including aneuploidy, observed in these disorders 
and to make ataxia telangiectasia patients prone to cancer 
(Wright et al., 1998; Spring et al., 2002; Shen et al., 2005; Murga 
et al., 2009; Lang et al., 2016; Yazinski and Zou, 2016; Blackford 
and Jackson, 2017; Quek et al., 2017). Previous studies showed 
that ATR localizes to centrosomes (Zhang et al., 2007) and 
that loss of ATR function causes centrosome overduplication 
(Alderton et al., 2004; Collis et al., 2008; Stiff et al., 2016) and 
genomic instability (Casper et al., 2004; Mokrani-Benhelli et 
al., 2013). In a recent study, Kabeche and colleagues reported a 
mechanism by which loss of ATR function leads to chromosome 
mis-segregation and aneuploidy (Kabeche et al., 2018; Saldivar 
and Cimprich, 2018). Specifically, they elegantly demonstrated 
that ATR localizes to centromeres and is required for proper 
chromosome segregation, in addition to and independent of its 
roles in DNA damage repair and replication stress responses 
(Kabeche et al., 2018). Although not discussed by Kabeche 
and colleagues or in previous publications, the links between 
ATR and mitosis provide an explanation for how reduced ATR 
function and subsequent aneuploidy may underlie the neuronal 
cell loss during development that leads to microcephaly and 
cognitive dysfunction, the major clinical, pathological, and 
disabling features of Seckel syndrome: reduced ATR function 
results in aneuploidy that leads to neuronal apoptosis.
In addition to Seckel syndrome, mosaic aneuploidy has 
been observed in brain neurons in ataxia telangiectasia itself 
(Iourov et al., 2007; Iourov et al., 2009a; Iourov et al., 2009b) 
and in Niemann–Pick type C disease (Granic and Potter, 
2013), and in peripheral cells in Nijmegen breakage syndrome 
(Vessey et al., 1999; Shimada et al., 2009; Shimada et al., 2010; 
Hou et al., 2012), Fanconi anemia (Nalepa et al., 2013), and 
xeroderma pigmentosum (Amiel et al., 2004). All of these 
developmental disorders are characterized by microcephaly or 
other evidence of poor neurogenesis and/or of neuronal loss, 
and all are associated with cognitive disfunction.
Mechanisms by Which Neuronal 
Aneuploidy and Apoptosis Can Arise
Because neurons have been traditionally considered to be 
post-mitotic (Bhardwaj et al., 2006), it has been unclear how 
extensive mosaic aneuploidy can arise in neurodegenerative 
or neurodevelopmental disorders. More recently, it has 
become appreciated that neurogenesis is more widespread 
than previously thought and that the capacity for neurogenesis 
continues into old age, even if not normally utilized (Zhao 
et  al., 2008; Spalding et al., 2013; Boldrini et al., 2018; 
Sorrells et al., 2018). In the adult brain, three processes have 
been identified that may generate the neuronal aneuploidy 
observed at autopsy in patients with AD, FTLD-MAPT, and 
other neurodegenerative and neurodevelopmental disorders. 
In principle, the generation and accumulation of aneuploidy 
in dividing or regenerating cell populations might arise by 
both genetic and environmental stressors at any time in life 
(discussed in Potter, 1991; Oromendia and Amon, 2014). 
Indeed, there is strong evidence that neurogenesis can occur 
throughout life in several regions of the brain (Zhao et al., 2008; 
Mu and Gage, 2011; Spalding et al., 2013; Ernst et al., 2014). 
Furthermore, data from many studies provide evidence that 
neurogenesis can be induced in many brain regions in adult 
mice and rats in response to brain damage and attempted self-
repair by the brain (Zhou et al., 2004; Zhao et al., 2008; Spalding 
et al., 2013; Zheng et al., 2013; Ibrahim et al., 2016), or as part of 
an ongoing process in the sub-ventricular/granular zone of the 
brain (Eriksson et al., 1998; Hallbergson et al., 2003; Sakamoto 
et al., 2014). Thus, neuronal damage and the mitotic defects 
evident in AD, FTLD-MAPT, and other neurodegenerative and 
neurodevelopmental disorders could result in the production 
of new aneuploid neurons, which would not be fully functional 
and would be particularly prone to apoptosis and degeneration. 
Indeed, aneuploidy has been shown to promote cell death, 
including neurodegeneration, in many experimental systems 
(Rajendran et al., 2008; Kai et al., 2009; Arendt et al., 2010; 
Oromendia and Amon, 2014).
The second potential mechanism for the generation of 
neuronal aneuploidy in neurodegenerative disease is cell cycle 
reentry. Neurons in the AD brain express phospho-proteins 
usually detected only during mitosis, such as cyclin B1, cyclin 
D1, cdc2, and Ki67 (Vincent et al., 1996; McShea et al., 1997; 
Vincent et al., 1997; Yang et al., 2001; Arendt, 2012). In AD mice, 
the loss of preexisting neurons induces the remaining neurons 
to reenter the cell cycle (Lopes et al., 2009). Indeed, Aβ has been 
shown to induce the expression of mitotic proteins and cell cycle 
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reentry in mature neurons in culture (Majd et al., 2008; Absalon 
et al., 2013; Seward et al., 2013), which we have confirmed (Nina 
Elder, unpublished observation).
The third potential mechanism for generating aneuploid 
neurons is based on the recent discovery that striatal 
astrocytes can transdifferentiate into new neurons capable 
of forming functional neuronal circuits with preexisting 
neurons following ischemic brain injury (Magnusson et al., 
2014; Duan et al., 2015). This finding suggests that at least 
some of the aneuploid neurons in AD and FTLD-MAPT 
brains may be derived from the aneuploid glia that we have 
shown are present in our preliminary and published studies. 
In additional preliminary studies, we have found that low 
numbers of primary astrocytes exposed to Aβ in culture can 
begin to express the neuronal marker NeuN (Nina Elder, 
unpublished observation). Taken together, these findings 
provide evidence that aneuploidy can arise de novo in mature 
neurons by cell cycle reactivation or can be carried over 
from previously dividing cells that generate new neurons. It 
is reasonable that age may exacerbate all of these processes 
because neuronal and non-neuronal aneuploidy have been 
shown to increase with age (Arendt et al., 2009; Yurov et al., 
2009; Yurov et al., 2010; Fischer et al., 2012; Fantin et al., 
2019). Aging is also associated with increasing total exposure 
to environmental stressors, some of which can promote 
chromosome missegregation and aneuploidy (for reviews, see 
Potter, 1991; Iourov et al., 2013).
In addition to the close and mechanistic association between 
aneuploidy and induced apoptosis discussed above, multiple 
reports in different systems have shown that aneuploid or 
other copy number variant cells are prone to degeneration/
apoptosis (Oromendia and Amon, 2014; Ohashi et al., 2015; 
Potter et al., 2016; Andriani et al., 2017; Chronister et al., 
2019). As mentioned earlier, Arendt and colleagues conducted 
a pathological study of AD patients’ brains across the disease 
spectrum and showed that neuronal aneuploidy arises before 
neurodegeneration or clinical symptoms are evident (Arendt 
et  al., 2010). Specifically, they found that the number of 
aneuploid neurons increases steadily from around 10% in 
normal controls to around 30% during the early preclinical 
stages of AD and then declines back to around 10% during the 
transition from preclinical AD to severe AD when neuronal loss 
occurs. In addition, they calculated that the loss of aneuploid, 
but not diploid, neurons accounted for 90% of the neuronal 
atrophy observed at autopsy of late-stage AD brains (Arendt 
et al., 2010). Based on their findings, it can be concluded that: 1) 
aneuploidy in neurons arises in the AD brain before extensive 
neuronal cell loss occurs and thus the aneuploidy is not likely 
to be caused by neurodegeneration/neuronal apoptosis, and 2) 
the vast majority of later neuronal cell loss selectively affects 
aneuploid neurons, indicating that the neurodegeneration 
is likely caused by a cell-autonomous cell cycle defect in the 
neurons themselves rather than by a tissue-wide mechanism 
(such as an unidentified, diffusible toxic insult released from 
damaged cells). Possible cell-autonomous effects of aneuploidy 
that could contribute to cell death include DNA replication 
stress (Yurov et al., 2011) and proteotoxic stress (Oromendia 
et al., 2012).
Linking Development and Aging: A 
Role for Catalysts in Age-Associated 
proteinopathies
In view of these considerations, we note that developmental 
disorders, such as Seckel syndrome, ataxia telangiectasia, 
Niemann–Pick type C, Nijmegen breakage syndrome, Fanconi 
anemia, and xeroderma pigmentosum, all of which lead to 
neuronal apoptosis, degeneration, and microcephaly, result 
from mutations in genes whose products impact mitosis, directly 
or indirectly. In contrast, aging-associated neurodegenerative 
diseases, such as AD, FTLD, Lewy body disease (Yang et al., 
2015), and potentially Huntington’s disease (Sathasivam et al., 
2001; Elos and Caneus et al., unpublished results) and prion 
disease (Basu et al., 1998; Borchsenius et al., 2000; Nieznanska 
et al., 2012) all develop abnormal protein deposits in the brain 
in addition to aneuploidy. The formation of these deposits 
apparently involves not only the seminal protein itself but often 
requires inflammation or other aging-associated catalysts. For 
example, inheritance of the ε4 allele of the apolipoprotein E 
(APOE) gene is the strongest risk factor for the development 
of AD besides age itself. Interestingly, the APOE4 allele and 
an AD-linked PSEN1 polymorphism have each been shown to 
increase the risk of meiosis II chromosome segregation errors, 
leading to Down syndrome, and a mother carrying both the 
APOE4 allele and the PSEN1 polymorphism has an even higher 
risk of a trisomy 21 conception (Avramopoulos et al., 1996; 
Petersen et al., 2000; Rodriguez-Manotas et al., 2007; Bhaumik 
et al., 2017). Indeed, a recent study of older adults with Down 
syndrome reported that those who were APOE4 carriers 
were at increased risk of both dementia and death (Hithersay 
et al., 2019). Notably, ApoE, particularly ApoE4, catalyzes the 
conversion of Aβ into the toxic oligomers that directly disrupt 
the mitotic spindle and chromosome segregation and also leads 
to amyloid deposition (Potter and Wisniewski, 2012). A similar 
co-pathological protein likely exists in prion disease too, 
although this exacerbating protein has been shown not to be 
ApoE (Tatzelt et al., 1996). This two-hit mechanism involving a 
mutant aggregation-prone protein plus an amyloid catalyst may 
underlie the fact that, in AD, amyloid deposits, symptoms, and 
aneuploidy all arise with aging. Similar two-hit mechanisms 
may underlie other aging-associated neurodegenerative 
diseases and neurodevelopmental disorders. Furthermore, 
the region-specific expression of the second hit (such as with 
ApoE in AD) may underlie the region-specific pathology and 
neuronal loss in different disorders.
Constitutional Aneuploidy in the Normal 
Brain
In addition to its association with neurodegenerative and 
neurodevelopmental disorders, aneuploidy and possibly copy 
number variations on a smaller scale are considered potential 
contributors to diversity in brain function (Iourov et al., 
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2009b; Mkrtchyan et al., 2010; Bushman and Chun, 2013; 
Rohrback et al., 2018). Although extensive whole chromosome 
aneuploidy has not been found by all investigators (Knouse 
et al., 2014), it is likely that new methods will reveal more 
aneuploid cells in both normal aged and diseased brains 
(Caneus et al., 2017).
summary
In sum, recent work reinforces our emerging understanding 
of the important role that chromosome mis-segregation and 
mosaic aneuploidy in neurons may play in an ever-growing list 
of both neurodevelopmental disorders and aging-associated 
neurodegenerative disorders (Figure 1). These findings have 
potentially important implications for the development of: 1) 
novel diagnoses because, as discussed, in addition to neurons 
in the brain, peripheral cells also exhibit mosaic aneuploidy 
in these disorders, and 2) innovative preventions/treatments 
because interventions can now be sought that specifically 
promote correct chromosome segregation in the presence of 
aneugenic mutations and/or aneugenic protein structures that 
lead to neuropathogenesis.
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